

Inhibition of MEK alone and in combination with ALK inhibition suppresses tumor growth in a mouse model of ALK-positive lung cancer.

Shrestha, N.¹, Bland, A.R.¹, Bower, R.L.¹, Rosengren, R.J.¹, Ashton, J.C^{1*}.

1. Department of Pharmacology & Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.

Running Title: MEK for ALK-positive lung cancer

***Corresponding author:** Associate Professor John C Ashton

Address: Department of Pharmacology & Toxicology, School of Biomedical Sciences,
University of Otago, Dunedin, New Zealand

Tel: +6434793040

Email address: john.ashton@otago.ac.nz

Number of words in Abstract: 168

Number of words in Introduction: 661

Number of words in Discussion: 1080

Abbreviation

ALT	Aminotransferase
BIM	Bcl-2 like protein 11
CYP3A	Cytochrome P450 isoform
DAB	3,3-diaminobenzidine tetrahydrochloride
HER2	Human epidermal growth factor receptor 2
KRAS	Kirsten rat sarcoma
MEK	Mitogen activated protein kinase kinase
MVD	Micro-vessel density
NSCLC	Non-small cell lung cancer
ORR	Objective response rate
PARP	Poly (ADP-ribose) polymerase
PFS	Progression free survival
TdT	terminal deoxynucleotidyl transferase
TKI	Tyrosine kinase inhibitor

Abstract

Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer most commonly arises through EML4-ALK chromosomal fusion. We have previously demonstrated that combination of the ALK inhibitor crizotinib with the MEK inhibitor selumetinib was highly effective at reducing cell viability of ALK-positive NSCLC (H3122) cells. In this study, we further investigated the efficacy of crizotinib and selumetinib combination therapy in an *in vivo* xenograft model of ALK-positive lung cancer. Crizotinib decreased tumor volume by 52% compared to control, and the drug combination reduced tumor growth compared to crizotinib. In addition, MEK inhibition alone reduced tumor growth by 59% compared to control. Crizotinib, selumetinib, alone and in combination were non-toxic at the dose of 25 mg/kg with values for ALT (< 80 U/L) and creatinine (<2 mg/dL) within the normal range. Our results support the combined use of crizotinib with selumetinib in ALK-positive lung cancer but raise the possibility that a sufficient dose of a MEK inhibitor alone may be as effective as adding a MEK inhibitor to an ALK inhibitor.

Significance Statement

This study contains *in vivo* evidence supporting the use of combination MEK inhibitors in ALK+ lung cancer research, both singularly and in combination with ALK inhibitors. Contrary to previously published reports, our results suggest that is possible to gain much of the benefit from combination treatment with a MEK inhibitor alone, at a tolerable dose.

Introduction

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide accounting for approximately 80–85% of lung cancer cases (Ettinger et al., 2013; Ferlay et al., 2015). Anaplastic lymphoma kinase (ALK) gene rearrangements are found in 2-7% of NSCLC, where they are key oncogenic drivers that promote cancer cell proliferation and survival, through activation of intra-cellular signalling pathways (Perner et al., 2008; Roskoski, 2013; Soda et al., 2007).

Crizotinib is a first generation ALK tyrosine kinase inhibitor (TKI) approved by the Food and Drug Administration and the European Medicines Agency for the treatment of ALK-positive NSCLC (Camidge et al., 2012; Kazandjian et al., 2014; Kwak et al., 2010). Based on a Phase I dose escalation study, the maximum tolerated dose for crizotinib is 250 mg p.o. twice daily (Kwak et al., 2010; Kwak et al., 2009). Treatment related adverse events are mostly grade 1 or 2 such as gastrointestinal upset, visual disturbances and peripheral oedema. Grade 3 or 4 adverse events including neutropaenia, raised alanine aminotransferase (ALT) enzymes, lymphopaenia and pneumonitis were observed in a minority of patients (Camidge et al., 2012).

In subsequent trials, ALK-positive NSCLC patients were highly responsive to crizotinib with an objective response rate (ORR) of 74% and progression free survival (PFS) of 10.9 months compared to standard chemotherapy, which has an ORR of 45% and PFS of 7 months (Solomon et al., 2014). However, the majority of patients develop resistance typically within 12 months of beginning therapy. Mechanisms of resistance include ALK gene alterations such as ALK point mutation or copy number gain and activation of bypass signalling via the activation of other oncogenes such as insulin-like growth factor-1 receptor (IGF-1R), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2) and cKIT or mutations in EGFR or kirsten rat sarcoma (KRAS) (Choi et al., 2010; Doebele et al., 2012; Katayama et al., 2012; Sasaki et al., 2011; Zhang et al., 2011). Although new generation ALK inhibitors such as alectinib and ceritinib have extended survival times, new therapeutic strategies that overcome resistance are needed.

Previously, we have demonstrated that combination of crizotinib and selumetinib strongly inhibited the growth of ALK-positive NSCLC cells. This resulted from a reduction in MAPK signalling that in-turn decreased cell proliferation and increased apoptosis via increased expression of apoptotic markers BIM, cleaved caspase, cleaved PARP and the cyclin dependent kinase inhibitor, p27 and decreased expression of the cell proliferation marker, cyclin D1

(Shrestha et al., 2019). These results supported the finding of Hrustanovic et al. who found that dual inhibition of ALK/MEK delayed the emergence of drug resistant ALK-positive NSCLC cell growth compared to the single drug treatment (Hrustanovic et al., 2015).

In this study we investigated the efficacy of crizotinib and selumetinib combination treatment in an *in vivo* model of ALK-positive NSCLC. We found that both drugs, either alone or in combination, significantly decreased tumor growth compared to control. The combination of crizotinib and selumetinib significantly reduced tumor volume compared to all other treatments, but unexpectedly, selumetinib alone was almost as effective as the two drugs combined. We also investigated the toxicity of crizotinib and selumetinib in Balb/c mice. We found no evidence of toxicity from the drugs either singularly or in combination. Body and organ weights were unchanged, and plasma markers for liver and kidney injury were within the normal range. Lastly, we examined if crizotinib, selumetinib or the combination could modulate the catalytic activity of hepatic CYP3A as both drugs are substrates for the cytochrome P450 isoform CYP3A (Johnson et al., 2015; Mao et al., 2013). However, we did not detect an effect on hepatic microsomal CYP3A catalytic activity, suggesting that the two drugs do not cause competitive inhibition of each other's metabolism *in vivo*. Our findings support clinical investigation of crizotinib and selumetinib combination therapy in ALK-positive NSCLC, but also suggest that much of the benefit of combination treatment may be gained by the use of MEK inhibitors as a monotherapy.

Methods and Materials

Materials

The human adenocarcinoma ALK-positive non-small cell lung cancer (H3122) cell line harbouring EML4-ALK variant 1 fusion gene was kindly gifted from Professor Daniel Costa, Harvard University. Selumetinib and crizotinib were purchased from LC laboratories (Woburn, Massachusetts, USA). Roswell Park Memorial Institute medium (RPMI), bovine serum albumin (BSA), foetal bovine serum (FBS), penicillin/streptomycin were purchased from Life Technologies. DAB substrate kit and streptavidin-horseradish peroxidase were purchased from BD Biosciences (San Diego, CA, USA). Haematoxylin quick stain (QS) (modified Mayer's formula), avidin-biotin blocking kit were purchased from Vector Laboratories (Burlingame, CA, USA). Hydrogen peroxide (30%) and ApopTag peroxidase in situ apoptosis detection kit were obtained from Merck (Billerica, MA, USA). Alanine aminotransferase (ALT) assay kit and cryomatrix were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Creatinine colourimetric assay kit was purchased from Cayman Chemical Company (Ann Arbor, MI, USA). Matrigel was purchased from Sigma Aldrich (St Louis, MO, USA). Ki67 was purchased from Abcam (Cambridge, UK). CD105 was obtained from Antibodies-online.com (Limerick, USA). CYP3A and GAPDH antibody were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Polyclonal goat anti-rabbit immunoglobulin/biotinylated were purchased from Dako, Denmark.

Animal housing and care

Male nude (Nu/J) were purchased from Animal Resource Centre, Australia. Male Balb/c mice were purchased from the Hercus-Taieri Resource Unit, Dunedin, New Zealand. Mice were housed in pathogen-free condition supplied with free access to sterile water and food (Reliance rodent diet). The room was maintained at temperature of 21-24°C on a scheduled 12 h light/dark cycle and mice were acclimatised for 4 days prior to experiment. All animal experiments were approved by the University of Otago Animal Ethics Committee (AEC Approval No. 18-21 and 18-82).

Drug efficacy in a xenograft model of lung cancer

An ALK-positive NSCLC xenograft model was established by subcutaneous injection of H3122 cells (2×10^6 cells in 50 μ l Matrigel and 50 μ L of media) in the flank region of Nu/J mice. Once the tumor volume had reached $\sim 100 \text{ mm}^3$, the mice were randomised into four

groups (n=7). Each group received either vehicle (25% DMSO/75% olive oil, 5 ml/kg), crizotinib 25 mg/kg, selumetinib 25 mg/kg or their combination p.o once daily for 2 weeks. The doses were chosen on the basis that it is equivalent to a well-tolerated human dose (Nencioni et al., 2014; Zhou et al., 2012). Body weight and tumor volume were measured daily. Tumor volume (mm³) was calculated by multiplying length (L) x height (H) x width (W). At the end of treatment, mice were euthanised by carbon dioxide inhalation and full necropsies were performed.

Immunohistochemistry

Tumors were fixed in 4% paraformaldehyde, embedded in cryomatrix and sectioned (6 µm). The sections were fixed with acetone and endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 20 min. Heat mediated antigen retrieval was performed by incubating sections in 0.01 M citrate buffer pH 6. Sections were then incubated with blocking buffer (normal goat serum, BSA, avidin) for 1 h followed by overnight incubation with primary antibody (CD105 1:100, Ki67 1:100 along with biotin) at 4°C. For negative controls, antibody was replaced with PBS. Sections were incubated with biotinylated secondary antibody for 30 min and signal was detected using 3,3-diaminobenzidine tetrahydrochloride (DAB). Sections were counterstained with haematoxylin, dehydrated and mounted. Slides were then scanned with Aperio Image ScanScope System (Leica, Chicago, IL, USA). The nuclear image analysis algorithm was used to quantify Ki67 stained (proliferative) cells. The microvessel analysis algorithm was used to quantify the MVD at a dark- and light-staining threshold of 180 and 210, respectively.

The TUNEL assay was performed to visualise apoptotic cells using ApopTag *in situ* detection kit as per the manufacture's instruction. Briefly, sections were fixed in ethanol-acetic acid solution (2:1) and incubated with 3% hydrogen peroxide. Sections were then incubated with equilibrating buffer followed by terminal deoxynucleotidyl transferase (TdT) enzyme. For negative control, TdT enzyme was replaced with PBS. The reaction was stop using stop/wash buffer and incubated with anti-digoxigenin peroxidase. The sections were stained with DAB, counterstained with haematoxylin, dehydrated and mounted. Slides were then scanned with Aperio Image ScanScope System (Leica, Chicago, IL, USA). The nuclear image analysis algorithm was used to quantify TUNEL stained (apoptotic) cells.

Preclinical Toxicity Study

Male Balb/c mice were randomly divided into four groups with each group containing 6 mice except crizotinib (n=5) and combination (n=7). Mice from each group received either vehicle (25% DMSO/ 75% olive oil, 5 ml/kg), crizotinib 25 mg/kg, selumetinib 25 mg/kg or their combination p.o once daily for 2 weeks. For positive control of CYP3A assay, mice (n=5) were orally administered daily with dexamethasone (50 mg/kg) for 4 days. At the end of treatment, mice were euthanised by carbon dioxide inhalation and full necropsies were performed. Plasma was used to measure ALT activity and creatinine levels as markers for liver and kidney injury, respectively.

Erythromycin N-demethylation

Hepatic microsomes were prepared from treated mice as previously described (Guengerich, 2014). The erythromycin N-demethylation assay was then performed to determine the catalytic activity of CYP3A as described previously (Kitada et al., 1988). Reaction mixture containing 1 mg of microsomal protein and 0.45 ml erythromycin buffer (0.1 M phosphate buffer pH 7.4, 0.1 mM EDTA and 0.4 mM erythromycin) was prepared and incubated for 2 min at 37°C in a shaking water bath. The reaction was initiated by addition of 0.05 ml of 50 mM NADPH. After 30 min, 0.33 ml of 15% zinc sulphate was added and was incubated for 5 min at room temperature. Next, 0.33 ml of saturated barium hydroxide was added and was further incubated for 5 min. The samples were then centrifuged for 10 min. 0.83 ml of supernatant was added to 0.33 ml of Nash reagent (30% ammonium acetate and 0.4% acetyl acetone). The samples were then incubated for 30 min at 60°C, centrifuged and absorbance of supernatant was measured on visible spectrophotometer at 415 nm. Catalytic activity of CYP3A was calculated and expressed in nmol/mg/min.

Statistical analysis

Tumor volume was analysed using a two-way ANOVA mixed effect coupled with a Tukey post-hoc test, with a day of treatment as a repeated-measures factor and drug treatment as an independent factor. All other data that were independent of time were analysed using a one-way ANOVA coupled with Bonferroni post-hoc test. Data are presented as the mean \pm SD. $p < 0.05$ was the minimal requirement for a statistically significant difference. Data were tested for normality using the Kolmogorov-Smirnov test, and non-normal data log-transformed before further analysis.

Results

Combination of crizotinib and selumetinib enhanced antitumor effect in an ALK-positive NSCLC xenograft mouse model

Orally administered crizotinib (25 mg/kg), selumetinib (25 mg/kg) and their combination were administered daily by oral gavage for 14 days in Nu/J mice bearing H3122 xenografts. There were slight decreases in the body weight of the mice in all four groups (Table 1, but no statistically significant difference in body weight between treatment groups and vehicle control). Similarly, we found no significant differences in organ weight (expressed as % of body weight) among the treatment groups compared to vehicle control (Table 1).

Crizotinib, selumetinib and their combination treatment significantly decreased tumor volume by 52%, 59% and 76% compared to control. Combination treatment showed significant decreases in tumor volume (76%) compared to the crizotinib (52%, $p < 0.0001$, two-way ANOVA) and the selumetinib (56%, $p < 0.05$, two-way ANOVA) single drug treatments. Of particular note, unexpectedly mice treated with selumetinib alone had decreased tumor growth similar to that for crizotinib alone (Figure 1).

Neoplastic histology was confirmed by Ki67 immunolabelling (Fig. 2A). Ki67 is a marker of proliferating cells, and 60-70% of cells in tumors from all treatment groups were Ki67 positive. Because selumetinib alone suppressed tumor growth more than the ALK inhibitor crizotinib, we hypothesised that a possible mechanism that could explain this could be inhibition of angiogenesis by interference with ERK signalling (Murphy et al., 2006). We, therefore, carried out immunohistochemistry for CD105, an endothelial cell marker. However, all tumors from all treatment groups were well vascularised as visualised with CD105 staining, with no statistically significant difference in micro-vessel density (MVD) among the treatment groups and vehicle control (Fig. 2C, $p > 0.05$, one-way ANOVA).

We then hypothesised that the frequency of apoptotic cells would be greatest in the treatment groups with the greatest tumor suppression (i.e., selumetinib alone and crizotinib plus selumetinib combination). However, histological staining for apoptosis using TUNEL unexpectedly revealed that the highest frequency of apoptotic cells was in tumors from crizotinib treated mice. By contrast, tumors from mice treated for 14 days with selumetinib either alone or in combination with crizotinib did not show a significantly different frequency of apoptotic cells compared with control mice (Fig. 2B, $p > 0.05$, one-way ANOVA).

Preclinical toxicity of crizotinib and selumetinib singular and combination treatment

To further investigate potential drug induced toxicity of crizotinib, selumetinib, and their combination, we treated Balb/c mice with the vehicle (DMSO/olive oil, 5 ml/kg), crizotinib (25 mg/kg), selumetinib (25 mg/kg) and their respective combination orally once daily for 14 days. Change in body weight was not significantly different between the treatment groups (Supplementary Table 1). Furthermore, there was no significant difference in organ weight between treatment groups and vehicle control for all major organs (Supplementary Table 1).

Next, to determine the effect of drugs on kidney and liver function, we measured plasma for ALT activity and creatinine levels. ALT activity in treatment groups was not significantly different from vehicle control. However, one mouse from the vehicle and crizotinib treated groups had ALT activity levels greater than 80 U/L (i.e., 126 and 89 U/L, respectively, Figure 3A). We further explored the histopathology of liver section by performing H and E staining. We found no histopathological differences in liver sections between treatment groups and vehicle control. We did not find necrotic cells or lesions in liver section from vehicle or drug treatment groups (Supplementary Figure 2). Moreover, there was no significant difference in creatinine level (a kidney function marker) between any of the treatment groups, as all mice had plasma creatinine values in the normal range (< 2 mg/dl) (Figure 3B).

Combination of crizotinib and selumetinib does not alter CYP3A activity *in vivo*.

We investigated whether crizotinib and selumetinib alone and in combination could alter activity of their major metabolising enzyme CYP3A. There was no significant change in CYP3A catalytic activity in single or combination treatment of crizotinib and selumetinib compared to vehicle control. Used as a positive control to check on assay validity, dexamethasone, a CYP3A inducer, significantly increased CYP3A catalytic activity compared to vehicle control ($p < 0.0001$, one-way ANOVA) (Figure 4A). Furthermore, Western blotting of microsomal protein showed no change in polypeptide levels of hepatic CYP3A by crizotinib, selumetinib or their combination (Figure 3B). Again, we observed a significant increase in CYP3A protein by dexamethasone compared to control (Figure 3C) ($p < 0.0001$, one-way ANOVA). These results suggest that neither crizotinib (25 mg/kg) nor selumetinib (25 mg/kg) nor a combination of the two alter the metabolism of either drug.

Discussion

We initially aimed to test the hypothesis that the combination of the MEK inhibitor selumetinib with the ALK inhibitor crizotinib would reduce tumor growth in a mouse model of ALK-positive NSCLC to a greater extent than crizotinib alone. In a previous study, the ALK and MEK inhibitors ceritinib and trametinib had been found to have such an effect (Hrustanovic et al., 2015). Moreover, we had previously found that the addition of selumetinib to crizotinib in cell-based assays profoundly suppressed ALK-positive cancer cell growth (Shrestha et al., 2019). In addition, the drug combination strongly suppressed ERK activation along with activation of downstream mediators of cell proliferation, and induction of mediators of apoptosis. Here we indeed found that the addition of selumetinib to crizotinib greatly reduced tumor growth compared to crizotinib alone (Fig. 1). However, unexpectedly selumetinib alone reduced tumor growth to almost to the same degree as the drug combination.

The difference between our results and those of Hrustanovic et al can be explained by dose; trametinib and selumetinib are similar in potency as MEK1 inhibitors (Wu & Park, 2015), but whereas Hrustanovic et al administered 1 mg/kg/day of trametinib, in the present study we administered 25 mg/kg/day of selumetinib. Nevertheless, the unexpected efficacy of selumetinib as a monotherapy *in vivo* does not support the hypothesis that dual MEK/ALK inhibition in ALK-positive cancer would add benefit beyond what could be achieved by a sufficient dose of a MEK inhibitor alone. This conclusion is supported by our toxicology results. Several studies have shown that both the crizotinib and selumetinib single drug treatments can induce adverse events that range from grade 1-2 to grade 3-4 (Camidge et al., 2012; Carvajal et al., 2014; Catalanotti et al., 2013). But in this study 25 mg/kg/day selumetinib did not elevate any of the measures of toxicity and so results comparable to combination drug treatment may be achieved by a MEK inhibitor alone at a tolerable dose.

Our results here are also in contrast to the results of our previously published *in vitro* experiments using H3122 cells, where selumetinib alone was 30-fold less potent at reducing cell viability than crizotinib alone (Shrestha et al., 2019). The reasons for the difference between these *in vitro* and *in vivo* results are unclear. The bioavailability of crizotinib (49%) (Kwon & Meagher, 2012) is only slightly less than that of selumetinib (62%) (Dymond et al., 2016b); an insufficient difference to explain the contrast between the results we obtained *in vitro* previously and *in vivo* in this study. We considered that possible differences in drug metabolism may help explain the results. Crizotinib is the primary substrates of CYP3A, and

according to *in vitro* studies causes moderate CYP3A protein inhibition and induces mRNA expression (Johnson et al., 2015; Mao et al., 2013; Tan et al., 2010). CYP3A4 is also the major enzyme responsible for selumetinib metabolism (Dymond et al., 2016a). We hypothesised then that CYP3A activity could be greater in mice treated with crizotinib, reducing crizotinib exposure compared to selumetinib administered alone. Nevertheless, we did not detect any differences in hepatic CYP3A activity nor polypeptide levels between crizotinib, selumetinib, or their combination compared to controls.

We carried out immunolabelling studies in further attempts to determine the reasons for the unexpected efficacy of selumetinib as a monotherapy in this study. Both selumetinib and crizotinib are known to have anti-tumor activity by increasing apoptosis and decreasing cell proliferation and angiogenesis (Cozzo et al., 2016; Dai et al., 2017; Takahashi et al., 2012). We first hypothesised that selumetinib may have had an anti-angiogenic effect through suppression of ERK activation (Murphy et al., 2006). Contrary to this hypothesis, both single and combination treatments did not reduce MVD in tumors taken from mice at day 14 compared to control as measured by CD105 immunolabelling (Fig. 2C). We then hypothesised that the selumetinib treated tumors would show increased frequency of apoptosis. Contrary to this hypothesis apoptosis was upregulated only in the crizotinib group compared to control (Fig. 2D). Finally, we hypothesised a cytostatic effect for selumetinib, but in contradiction to this there were no differences in proliferating cell frequency as measured by Ki67 immunolabelling (Fig. 2B).

Our *in vitro* study had demonstrated that crizotinib, selumetinib and their combination significantly increased G1 phase arrest using flow cytometry (Shrestha et al., 2019). However, Ki67 is present in G1, S, G2 and the mitotic phase, and only absent in the G0 phase of the cell cycle (Bruno & Darzynkiewicz, 1992; Guillaud et al., 1989). Therefore, Ki67 labelling may not accurately reflect the response to treatment, as it would not differentiate between cells in G1 arrest and other cells. Furthermore, in breast cancer clinical trials, the predictive value of Ki67 as an indicator of chemotherapy benefit remains controversial, as some trials reported that Ki67 was not related to treatment outcome (International Breast Cancer Study, 2002; Martey et al., 2019; Martey et al., 2017; Viale et al., 2008; Yerushalmi et al., 2010). Thus, Ki67 as an independent prognostic factor does not always reflect the response to treatment. Moreover, we have shown in a xenograft model of triple negative breast cancer that Ki67 in tumor slices from treated mice was unchanged compared control when analysed by univariate statistical analysis (Martey et al., 2017) even though significant tumor suppression was

observed. However, when multivariate analysis was performed, Ki67 played an important role as it was part of a biological network of 16 molecular targets that together predicted treatment outcome with a 95% success rate (Martey et al., 2019) Therefore, it is possible that Ki67 also contributes to a larger protein network in the suppression of H3122 xenograft tumors.

Suppression of ERK activation is also known to stimulate T-cells activation in some cancers (Ebert et al., 2016). It is highly unlikely that this could account for our results, as the xenograft model employed athymic mice.

Further studies are needed to ascertain the translatability of these findings to humans (Nair et al., 2018). Since beginning these studies recruitment has started for a clinical trial investigating the use of trametinib with ceritinib in ALK-positive NSCLC (Blakely, 2019), but there are no trials to our knowledge investigating selumetinib in similar patients. We used H3122 cells as they contain the most common ELM4-ALK variant (variant 1) which is highly sensitive to ALK inhibitors (particularly to crizotinib) (Cha et al., 2016; Wilson et al., 2017). Cells modelling other less common ELM4-ALK variants, although less clinically relevant, could be tested to ascertain if these results are applicable to other forms of lung cancer.

Acknowledgments

We would like to thank Ms. Mhairi Nimick from Department of Pharmacology and Toxicology for her technical support during development of Xenograft model.

Authorship Contributions

Participated in research design: Shrestha, Rosengren, Ashton.

Conducted experiments: Shrestha, Bland, Bower.

Performed data analysis: Shrestha, Ashton.

Wrote or contributed to writing of the manuscript: Shrestha, Ashton, Rosengren.

References

- Blakely, C. (2019). Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC). Retrieved from <https://clinicaltrials.ucsf.edu/trial/NCT03087448>
- Bruno, S., & Darzynkiewicz, Z. (1992). Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. *Cell Prolif*, 25(1), 31-40. doi:10.1111/j.1365-2184.1992.tb01435.x
- Camidge, D. R., Bang, Y. J., Kwak, E. L., Iafrate, A. J., Varella-Garcia, M., Fox, S. B., Riely, G. J., Solomon, B., Ou, S. H. I., Kim, D. W., Salgia, R., Fidias, P., Engelman, J. A., Gandhi, L., Jänne, P. A., Costa, D. B., Shapiro, G. I., LoRusso, P., Ruffner, K., Stephenson, P., Tang, Y., Wilner, K., Clark, J. W., & Shaw, A. T. (2012). Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. *The Lancet Oncology*, 13(10), 1011-1019. doi:10.1016/S1470-2045(12)70344-3
- Carvajal, R. D., Sosman, J. A., Quevedo, J. F., Milhem, M. M., Joshua, A. M., Kudchadkar, R. R., Linette, G. P., Gajewski, T. F., Lutzky, J., Lawson, D. H., Lao, C. D., Flynn, P. J., Albertini, M. R., Sato, T., Lewis, K., Doyle, A., Ancell, K., Panageas, K. S., Bluth, M., Hedvat, C., Erinjeri, J., Ambrosini, G., Marr, B., Abramson, D. H., Dickson, M. A., Wolchok, J. D., Chapman, P. B., & Schwartz, G. K. (2014). Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma. *Jama*, 311(23), 2397-2397. doi:10.1001/jama.2014.6096
- Catalanotti, F., Solit, D. B., Pulitzer, M. P., Berger, M. F., Scott, S. N., Iyriboz, T., Lacouture, M. E., Panageas, K. S., Wolchok, J. D., Carvajal, R. D., Schwartz, G. K., Rosen, N., & Chapman, P. B. (2013). Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. *Clinical Cancer Research*, 19(8), 2257-2264. doi:10.1158/1078-0432.CCR-12-3476
- Cha, Y. J., Kim, H. R., & Shim, H. S. (2016). Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants. *J Transl Med*, 14(1), 296. doi:10.1186/s12967-016-1061-z
- Choi, Y. L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., Nakajima, T., Yatabe, Y., Takeuchi, K., Hamada, T., Haruta, H., Ishikawa, Y., Kimura, H., Mitsudomi, T., Tanio, Y., Mano, H., & Group, A. L. K. L. C. S. (2010). EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. *N Engl J Med*, 363(18), 1734-1739. doi:10.1056/NEJMoa1007478
- Doebele, R. C., Pilling, A. B., Aisner, D. L., Kutateladze, T. G., Le, A. T., Weickhardt, A. J., Kondo, K. L., Linderman, D. J., Heasley, L. E., Franklin, W. A., Varella-Garcia, M., & Camidge, D. R. (2012). Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. *Clinical Cancer Research*, 18(5), 1472-1482. doi:10.1158/1078-0432.CCR-11-2906
- Dymond, A. W., Howes, C., Pattison, C., So, K., Mariani, G., Savage, M., Mair, S., Ford, G., & Martin, P. (2016a). Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects. *Clinical Therapeutics*, 38(11), 2447-2458. doi:10.1016/j.clinthera.2016.09.002
- Dymond, A. W., Howes, C., Pattison, C., So, K., Mariani, G., Savage, M., Mair, S., Ford, G., & Martin, P. (2016b). Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects. *Clin Ther*, 38(11), 2447-2458. doi:10.1016/j.clinthera.2016.09.002
- Ebert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S. E., Maecker, H., Irving, B. A., Kim, J. M., Belvin, M., & Mellman, I. (2016). MAP

- Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. *Immunity*, 44(3), 609-621.
doi:10.1016/j.immuni.2016.01.024
- Ettinger, D. S., Akerley, W., Borghaei, H., Chang, A. C., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Demmy, T. L., Govindan, R., Grannis, F. W., Jr., Grant, S. C., Horn, L., Jahan, T. M., Komaki, R., Kong, F. M., Kris, M. G., Krug, L. M., Lackner, R. P., Lennes, I. T., Loo, B. W., Jr., Martins, R., Otterson, G. A., Patel, J. D., Pinder-Schenck, M. C., Pisters, K. M., Reckamp, K., Riely, G. J., Rohren, E., Shapiro, T. A., Swanson, S. J., Tauer, K., Wood, D. E., Yang, S. C., Gregory, K., Hughes, M., & National comprehensive cancer, n. (2013). Non-small cell lung cancer, version 2.2013. *J Natl Compr Canc Netw*, 11(6), 645-653; quiz 653.
doi:10.6004/jnccn.2013.0084
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*, 136(5), E359-386.
doi:10.1002/ijc.29210
- Guengerich, P. F. (2014). Analysis and Characterization of Enzymes and Nucleic Acids Relevant to Toxicology. In A. W. Hayes & C. L. Kruger (Eds.), *Hayes' Principles and Methods of Toxicology, Sixth Edition* (pp. 1905-1964): Taylor & Francis.
- Guillaud, P., du Manoir, S., & Seigneurin, D. (1989). Quantification and topographical description of Ki-67 antibody labelling during the cell cycle of normal fibroblastic (MRC-5) and mammary tumour cell lines (MCF-7). *Anal Cell Pathol*, 1(1), 25-39.
- Hrustanovic, G., Olivas, V., Pazarentzos, E., Tulpule, A., Asthana, S., Blakely, C. M., Okimoto, R. A., Lin, L., Neel, D. S., Sabnis, A., Flanagan, J., Chan, E., Varella-Garcia, M., Aisner, D. L., Vaishnavi, A., Ou, S.-H. I., Collisson, E. A., Ichihara, E., Mack, P. C., Lovly, C. M., Karachaliou, N., Rosell, R., Riess, J. W., Doebele, R. C., & Bivona, T. G. (2015). RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. *Nature Medicine*, 21(9), 1038-1047.
doi:10.1038/nm.3930
- International Breast Cancer Study, G. (2002). Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. *J Natl Cancer Inst*, 94(14), 1054-1065. doi:10.1093/jnci/94.14.1054
- Johnson, T. R., Tan, W., Goulet, L., Smith, E. B., Yamazaki, S., Walker, G. S., O'Gorman, M. T., Bedarida, G., Zou, H. Y., Christensen, J. G., Nguyen, L. N., Shen, Z., Dalvie, D., Bello, A., & Smith, B. J. (2015). Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects. *Xenobiotica*, 45(1), 45-59. doi:10.3109/00498254.2014.941964
- Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M., Solomon, B. J., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C., Drew, L., Saeh, J. C., Crosby, K., Sequist, L. V., Iafrate, A. J., & Engelman, J. A. (2012). Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers. *Science Translational Medicine*, 4(120), 120ra117-120ra117. doi:10.1126/scitranslmed.3003316
- Kazandjian, D., Blumenthal, G. M., Chen, H. Y., He, K., Patel, M., Justice, R., Keegan, P., & Pazdur, R. (2014). FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements. *The Oncologist*, 19(10), e5-e11. doi:10.1634/theoncologist.2014-0241
- Kitada, M., Igoshi, N., Kamataki, T., Itahashi, K., Imaoka, S., Komori, M., Funae, Y., Rikihisa, T., & Kanakubo, Y. (1988). Immunochemical similarity of P-450 HFLa, a form of cytochrome P-450 in human fetal livers, to a form of rat liver cytochrome P-

- 450 inducible by macrolide antibiotics. *Arch Biochem Biophys*, 264(1), 61-66.
doi:10.1016/0003-9861(88)90570-x
- Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., & Costa, D. B. (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *New England Journal of Medicine*, 363(18), 1693-1703.
- Kwak, E. L., Camidge, D., Clark, J., Shapiro, G., Maki, R., Ratain, M., Solomon, B., Bang, Y., Ou, S., & Salgia, R. (2009). G6 Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. *European Journal of Cancer Supplements*, 7(3), 8.
- Kwon, J., & Meagher, A. (2012). Crizotinib: a breakthrough for targeted therapies in lung cancer. *J Adv Pract Oncol*, 3(4), 267-272. doi:10.6004/jadpro.2012.3.4.8
- Mao, J., Johnson, T. R., Shen, Z., & Yamazaki, S. (2013). Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. *Drug Metab Dispos*, 41(2), 343-352. doi:10.1124/dmd.112.049114
- Martey, O., Greish, K., Smith, P. F., & Rosengren, R. J. (2019). A multivariate statistical analysis of the effects of styrene maleic acid encapsulated RL71 in a xenograft model of triple negative breast cancer. *J Biol Methods*, 6(4), e121.
doi:10.14440/jbm.2019.306
- Martey, O., Nimick, M., Taurin, S., Sundararajan, V., Greish, K., & Rosengren, R. J. (2017). Styrene maleic acid-encapsulated RL71 micelles suppress tumor growth in a murine xenograft model of triple negative breast cancer. *Int J Nanomedicine*, 12, 7225-7237.
doi:10.2147/IJN.S148908
- Murphy, D. A., Makonnen, S., Lassoued, W., Feldman, M. D., Carter, C., & Lee, W. M. (2006). Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). *Am J Pathol*, 169(5), 1875-1885.
doi:10.2353/ajpath.2006.050711
- Nair, A., Morsy, M. A., & Jacob, S. (2018). Dose translation between laboratory animals and human in preclinical and clinical phases of drug development. *Drug Dev Res*.
doi:10.1002/ddr.21461
- Nencioni, A., Caffa, I., Raffaghello, L., Montecucco, F., Cea, M., Monacelli, F., Grossi, F., Patrone, F., Odetti, P., & Ballestrero, A. (2014). Potentiation of crizotinib activity by fasting cycles in an ALK+ lung cancer model. In: American Society of Clinical Oncology.
- Perner, S., Wagner, P. L., Demichelis, F., Mehra, R., Lafargue, C. J., Moss, B. J., Arbogast, S., Soltermann, A., Weder, W., Giordano, T. J., Beer, D. G., Rickman, D. S., Chinnaiyan, A. M., Moch, H., & Rubin, M. A. (2008). EML4-ALK fusion lung cancer: a rare acquired event. *Neoplasia*, 10(3), 298-302. doi:10.1593/neo.07878
- Roskoski, R. (2013). Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition. *Pharmacological Research*, 68(1), 68-94.
doi:10.1016/j.phrs.2012.11.007
- Sasaki, T., Koivunen, J., Ogino, A., Yanagita, M., Nikiforow, S., Zheng, W., Lathan, C., Marcoux, J. P., Du, J., Okuda, K., Capelletti, M., Shimamura, T., Ercan, D., Stumpfova, M., Xiao, Y., Weremowicz, S., Butaney, M., Heon, S., Wilner, K., Christensen, J. G., Eck, M. J., Wong, K. K., Lindeman, N., Gray, N. S., Rodig, S. J., & Jänne, P. A. (2011). A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. *Cancer Research*, 71(18), 6051-6060.
doi:10.1158/0008-5472.CAN-11-1340

- Shrestha, N., Nimick, M., Dass, P., Rosengren, R. J., & Ashton, J. C. (2019). Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer. *Sci Rep*, 9(1), 18842. doi:10.1038/s41598-019-55376-4
- Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-i., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y., & Mano, H. (2007). Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. *Nature*, 448(7153), 561-566. doi:10.1038/nature05945
- Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., Iyer, S., Reisman, A., Wilner, K. D., Tursi, J., & Blackhall, F. (2014). First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. *New England Journal of Medicine*, 371(23), 2167-2177. doi:10.1056/NEJMoa1408440
- Tan, W., Wilner, K. D., Bang, Y., Kwak, E. L., Maki, R. G., Camidge, D. R., Solomon, B. J., Ou, S. I., Salgia, R., & Clark, J. W. (2010). Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. *Journal of Clinical Oncology*, 28, 2596.
- Viale, G., Regan, M. M., Mastropasqua, M. G., Maffini, F., Maiorano, E., Colleoni, M., Price, K. N., Golouh, R., Perin, T., Brown, R. W., Kovacs, A., Pillay, K., Ohlschlegel, C., Gusterson, B. A., Castiglione-Gertsch, M., Gelber, R. D., Goldhirsch, A., Coates, A. S., & International Breast Cancer Study, G. (2008). Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. *J Natl Cancer Inst*, 100(3), 207-212. doi:10.1093/jnci/djm289
- Wilson, C., Nimick, M., Nehoff, H., & Ashton, J. C. (2017). ALK and IGF-1R as independent targets in crizotinib resistant lung cancer. *Sci Rep*, 7(1), 13955. doi:10.1038/s41598-017-14289-w
- Wu, P. K., & Park, J. I. (2015). MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms. *Semin Oncol*, 42(6), 849-862. doi:10.1053/j.seminoncol.2015.09.023
- Yerushalmi, R., Woods, R., Ravdin, P. M., Hayes, M. M., & Gelmon, K. A. (2010). Ki67 in breast cancer: prognostic and predictive potential. *Lancet Oncol*, 11(2), 174-183. doi:10.1016/S1470-2045(09)70262-1
- Zhang, S., Wang, F., Keats, J., Zhu, X., Ning, Y., Wardwell, S. D., Moran, L., Mohemmad, Q. K., Anjum, R., Wang, Y., Narasimhan, N. I., Dalgarno, D., Shakespeare, W. C., Miret, J. J., Clackson, T., & Rivera, V. M. (2011). Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. *Chemical Biology and Drug Design*, 78(6), 999-1005. doi:10.1111/j.1747-0285.2011.01239.x
- Zhou, W. j., Zhang, X., Cheng, C., Wang, F., Wang, X. k., Liang, Y. j., To, K. K. W., Zhou, W., Huang, H. b., & Fu, L. w. (2012). Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein. *British journal of pharmacology*, 166(5), 1669-1683.

Footnotes

Funding

This work was supported by a University of Otago Research Grant (grant number 0119-0520).

Figure Legends

Figure 1 : Combination of crizotinib and selumetinib significantly suppresses tumor volume compared to single drug treatment in a mouse xenograft model of H3122 lung adenocarcinoma. H3122 xenograft mice were orally administered with a vehicle (olive oil), crizotinib (25 mg/kg), selumetinib (25 mg/kg) and their combination daily for 2 weeks. Significance was determined by mixed-model two-way ANOVA with Tukey post-hoc tests. All data are presented as mean \pm SD from n=7. Statistical differences between the growth curves as a whole are indicated with asterisks; * $p < 0.05$, **** $p < 0.0001$.

Figure 2 : Effect of combination treatment on markers of cell proliferation, apoptosis and angiogenesis. The H3122 xenograft mice were orally gavaged daily with vehicle (olive oil), crizotinib (25 mg/kg), selumetinib (25 mg/kg) and their combination for 2 weeks. Tumors were resected and analysed by IHC. **A.** Representative IHC staining of Ki67 (first column), CD105 (middle column) and TUNEL (Last column). **B.** Quantification of Ki67 positive cells using IHC nuclear image algorithm. **C.** Quantification of TUNEL positive cells using IHC nuclear image algorithm. **D.** Quantification of CD105 positive endothelial cells using microvessel algorithm. Significance was determined by one-way ANOVA with Bonferroni post-hoc tests. All data are presented as mean \pm SD from n=5. Multiple comparison among treatment groups and vehicle did not show significant difference in Ki67, CD105 and TUNEL staining ($p > 0.05$). Scale bar: 100 μ m.

Figure 3 : Effect of crizotinib, selumetinib and their combination on liver and kidney function in Balb/C mice. **A.** ALT activity **B.** Plasma creatinine levels after treatment with vehicle (25% DMSO/olive oil), crizotinib (25 mg/kg//daily), selumetinib (25 mg/kg//daily), and their combination for 2 weeks. Significance was determined by one-way-ANOVA with Bonferroni post-hoc test. All data are presented as mean \pm SD. None were significantly different.

Figure 4 : Crizotinib and selumetinib alone or in combination do not modulate CYP3A polypeptide levels or catalytic activity. Balb/c mice were orally gavaged daily with vehicle (25% DMSO/olive oil), crizotinib (25 mg/kg), selumetinib (25 mg/kg) and their combination for 2 weeks. Liver was harvested and microsomes were prepared. **A.** CYP3A catalytic activity **B.** Representative Western blots of CYP3A. **C.** Densitometry of Western blots of CYP3A. V: vehicle, C: crizotinib, S: selumetinib, C+S: combination, D: dexamethasone **C.** Densitometry

of Western blots of CYP3A. V: Significance was determined by one-way-ANOVA with Bonferroni post-hoc test. All data are presented as mean \pm SD. ****p < 0.0001.

Table 1 : Body weight and organ weight of Nu/J mice

	Vehicle	Crizotinib 25 mg/kg	Selumetinib 25mg/kg	Crizotinib+ Selumetinib
Body Weight Change (g)	-0.2 ± 0.77	-0.45 ± 1.00	-0.4 ± 0.90	-0.03 ± 1.25
Organ Weight (% of Body Weight)				
Liver	6.05 ± 1.09	5.8 ± 0.56	6.2 ± 0.76	6.5 ± 0.38
Spleen	0.41 ± 0.18	0.49 ± 0.07	0.47 ± 0.07	0.49 ± 0.05
Lungs	1.09 ± 0.23	1.17 ± 0.13	1.16 ± 0.18	1.12 ± 0.2
Heart	0.49 ± 0.22	0.57 ± 0.06	0.57 ± 0.06	0.6 ± 0.04
Kidneys	1.73 ± 0.77	1.97 ± 0.08	2.07 ± 0.14	2.05 ± 0.07
Testes	0.8 ± 0.36	0.89 ± 0.13	0.9 ± 0.18	0.85 ± 0.12
Brain	1.19 ± 0.15	1.23 ± 0.17	1.18 ± 0.20	1.26 ± 0.18

Statistical significance was determined by one-way ANOVA with Bonferroni post-hoc test. All data are presented as mean ± SD from n = 7. Multiple comparison among treatment groups and vehicle did not show significant difference in both body and organ weight (p > 0.05).

Figure 1




Figure 2




Figure 3





Figure 4



For Journal of Pharmacology and Experimental Therapeutics (revised)

6 April 2020

Efficacy of crizotinib and selumetinib combination treatment in an *in vivo* xenograft model of ALK-positive lung cancer

Shrestha, N., Bland, A., Bower, R.L., Rosengren, R.J., Ashton, J.C¹.

Department of Pharmacology & Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.

1. Corresponding author

+6434793040

john.ashton@otago.ac.nz

Running Head: Efficacy of crizotinib and selumetinib combination therapy.

Keywords: Crizotinib; Selumetinib; ALK-positive lung cancer; Combination treatment

Table S1: Body weight and organ weight of Balb/c mice

	Vehicle control	Crizotinib 25 mg/kg	Selumetinib 25mg/kg	Crizotinib+ Selumetinib
Body Weight Change (g)	-1.23 ± 0.35	-0.28 ± 0.41	0.55 ± 0.73	0.8 ± 0.23
Organ Weight (% of Body Weight)				
Liver	5.60 ± 0.22	5.22 ± 0.22	4.92 ± 0.76	5.33 ± 0.20
Spleen	0.27 ± 0.008	0.28 ± 0.02	0.28 ± 0.02	0.29 ± 0.01
Lungs	1.15 ± 0.14	0.99 ± 0.15	0.87 ± 0.32	0.89 ± 0.08
Heart	0.61 ± 0.083	0.57 ± 0.06	0.55 ± 0.04	0.55 ± 0.03
Kidneys	2.02 ± 0.04	2.02 ± 0.09	1.89 ± 0.09	1.92 ± 0.03
Testes	0.70 ± 0.14	0.65 ± 0.05	0.93 ± 0.25	0.69 ± 0.01

Statistical significance was determined by one-way- ANOVA with Bonferroni post-hoc test. All data are presented as mean ± SEM from n = 6. Multiple comparison among treatment groups and vehicle did not show significant difference in both body and organ weight (p > 0.05).




Figure S1: Correlation between tumour volume and tumour weight.




Figure S2 : H and E staining of liver sections. Representative micrographs taken at 10x. Scale bar: 100 μ m.